Tech Company Financing Transactions
Albatroz Therapeutics Funding Round
Albatroz Therapeutics closed a $3 million funding round on 4/25/2023. Backers included Outram Bio and Seeds Capital.
Transaction Overview
Company Name
Announced On
4/25/2023
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Undisclosed
Investors
Outram Bio (Lead Investor) (Christopher Tan)
Seeds Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate the development of therapeutic antibodies against a novel target that degrades the extracellular matrix, a key contributor to cancer and arthritis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
21 Biopolis Rd, #02-03 Nucleos North Tower
Singapore, 138567
SG
Singapore, 138567
SG
Phone
Undisclosed
Website
Email Address
Overview
Albatroz Therapeutics is a pre-clinical stage biotechnology company with a mission to treat solid tumors and arthritic disorders that depend on extracellular matrix (ECM) remodeling.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Frederic Bard
Co-Founder
Guy Heathers
Browse more venture capital transactions:
Prev: 4/25/2023: Hydrosat venture capital transaction
Next: 4/25/2023: Virta venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs